Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12283742 | 0.81 | TSHR (0.39) | TSHRCYP2C19LMNASMN1; SMN2ALOX15 | |
| SCHEMBL7108959 | 0.81 | EPHX1 (0.38) | TSHRCYP2C19LMNAHIF1AHPGD | |
| SCHEMBL7108962 | 0.81 | EPHX1 (0.38) | TSHRCYP2C19LMNAHIF1AHPGD | |
| SCHEMBL10828218 | 0.81 | TSHR (0.39) | TSHRCYP2C19LMNASMN1; SMN2ALOX15 | |
| SCHEMBL6969767 | 0.79 | CYP2D6 (0.52) | TSHRCYP2C19LMNASMN1; SMN2ALOX15 | |
| SCHEMBL19355186 | 0.77 | SMN1; SMN2 (0.46) | TSHRCYP2C19LMNASMN1; SMN2HTT | |
| SCHEMBL606445 | 0.76 | — | — | |
| SCHEMBL19355183 | 0.76 | GAA (0.43) | TSHRLMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL20718465 | 0.75 | TSHR (0.37) | TSHRCYP2C19LMNASMN1; SMN2ALOX15 | |
| SCHEMBL20908170 | 0.75 | TSHR (0.37) | TSHRCYP2C19LMNASMN1; SMN2ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170342046-A1 | Fatty Acid Cysteine-Based Conjugates and Their Use in Treating Medical Disorders | CATABASIS PHARMACEUTICALS, INC. | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342046-A1 | Fatty Acid Cysteine-Based Conjugates and Their Use in Treating Medical Disorders | CPT2, FABP1, ACAA2 | TSHR 3232/4885CYP2C19 3277/4885LMNA 3607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.